OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial - Diener, HC; Dodick, DW; Aurora, SK; Turkel, CC; DeGryse, RE; Lipton, RB (Cephalalgia, 2010)
et al.